Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study.
Pauriah
Maheshwar
M
Struthers
Allan D
AD
Lang
Chim C
CC
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D015415:Biomarkers; D054316:Biomarkers, Pharmacological / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D002339:Carotid Arteries / Q000187:drug effects* / Q000473:pathology; D008078:Cholesterol, LDL / Q000097:blood*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D015203:Reproducibility of Results; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D015415:Biomarkers; D054316:Biomarkers, Pharmacological; D008078:Cholesterol, LDL; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D019821:Simvastatin